Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as REGN475 (SAR164877), Fasinumab, MT-5547, Fasinumab AI, Fasinumab PFS
REGN475 · 9 trials · 6 indications
WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in the index joint (knee or hip) in past 48 hours. It was calculated as the mean of the scores from the 5 individual questions scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (higher pain), where higher scores indicated higher pain.
Physical function referred to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale was a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated maximum difficulty.
The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.
The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.
The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.
The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.
Adjudicated arthropathy (AA) is a composite term that encompasses the following conditions: Rapidly progressive OA type 1 and 2, Subchondral insufficiency fractures, and Primary Osteonecrosis. AAs were also evaluated to determine if they met Destructive Arthropathy criteria.
DA is a unique clinical form of rapidly destructive arthropathy over and above that seen in the normal progression of OA. DA criteria can be associated with Rapidly Progressive OA type 2, Subchondral Insufficiency fracture, and Primary Osteonecrosis confirmed by an arthropathy adjudication committee.
Any participant with a peripheral sensory event that persisted for 2 months was referred for a neurology or other specialty consultation and reported as an adverse event of special interest (AESI).
Potential events of sympathetic nervous system (SNS) dysfunction were monitored throughout the study through physical examination, AE reporting, assessment of orthostatic hypotension, and the Survey of Autonomic Symptoms. Sympathetic nervous system dysfunction was diagnosed after consultation with an appropriate specialist, such as a neurologist and/or cardiologist.
All joint replacement surgery events regardless of cause at weeks 52 and 72. An end of study phone contact was also conducted approximately 52 weeks following the last dose of study drug.
Number of participants with potentially clinically significant abnormal values in hematology, chemistry, and urinalysis during the treatment period were reported. Clinical significance was determined by the investigator.
Number of participants with potentially clinically significant abnormal values in hematology, chemistry, and urinalysis during the post-treatment period were reported. Clinical significance was determined by the investigator.
Immunogenicity was characterized by ADA responses \& titers. Responses categories: Negative - ADA negative response at all time points, regardless of missing samples; Pre-existing immunoreactivity - ADA positive response at baseline with all post first dose negative results or positive response at baseline with all post first dose ADA responses less than (\<) 9-fold over baseline titer levels; Treatment-boosted response - positive response in the assay post first dose, greater than or equal to (≥) 9-fold over baseline titer levels, when baseline results are positive; Treatment-emergent response - ADA positive response in the fasinumab ADA assay post first dose when baseline results = negative or missing.
The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.
The WOMAC index is comprised of 24 parameters grouped in 3 subscales (pain-5 questions, physical function -17 questions and stiffness - 2 questions), with 0-10 grading of each question. The scores for each subscale are summed up, divided by number of questions, and each subscale is reported using Numerical Rating Scale score of 0-10. In addition to subscales, a total score is provided as the sum of normalized subscale scores divided by three, and reported using a Numerical Rating Scale score of 0-10. Higher scores indicate worse pain, stiffness and functional limitations.
Peroneal motor nerve conduction velocity was evaluated by electrical stimulation of the nerve and recorded the compound muscle action potential from surface electrodes overlying a muscle supplied by the nerve. Change from baseline in peroneal motor nerve conduction velocity at Week 16 was reported.
Peroneal motor nerve action potential amplitude was evaluated at ankle by electrical stimulation of the nerve and recorded the compound muscle action potential from surface electrodes overlying a muscle supplied by the nerve. Change from baseline in peroneal motor nerve action potential amplitude at Week 16 was reported.
Sural sensory nerve conduction velocity was evaluated by electrically stimulating sensory fibers and recorded the nerve action potential at a point further along that nerve. Change from baseline in sural sensory nerve conduction velocity at Week 16 was reported.
Sural sensory nerve action potential amplitude was evaluated by electrically stimulating sensory fibers and recorded the nerve action potential at a point further along that nerve. Change from baseline in sural sensory nerve action potential amplitude at Week 16 was reported.
Ulnar sensory nerve conduction velocity was evaluated by electrically stimulating sensory fibers and recorded the nerve action potential at a point further along that nerve. Change from baseline in ulnar sensory nerve conduction velocity at Week 16 was reported.
Ulnar sensory nerve action potential amplitude was evaluated by electrically stimulating sensory fibers and recorded the nerve action potential at a point further along that nerve. Change from baseline ulnar sensory nerve action potential amplitude at Week 16 was reported.
Average daily low back pain (LBP) was assessed on an 11-point numeric rating scale (NRS) and was defined as the average of the non-missing daily LBPI NRS scores for the 7 days before and including nominal visit. Participants described their average low back pain during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate higher pain.
| Arm | Type | Description |
|---|---|---|
| Dosing regimen 1 | EXPERIMENTAL | - |
| Dosing regimen 2 | EXPERIMENTAL | - |
| Dosing regimen 3 | EXPERIMENTAL | - |
| Dosing regimen 4 | EXPERIMENTAL | - |
| Fasinumab dosing regimen 1 | EXPERIMENTAL | Fasinumab Subcutaneous (SC) dosing regimen 1 and naproxen-matching placebo oral |
| Fasinumab dosing regimen 2 | EXPERIMENTAL | Fasinumab SC dosing regimen 2 and naproxen-matching placebo oral |
| Fasinumab-matching placebo and naproxen | EXPERIMENTAL | - |
| Fasinumab-matching placebo and naproxen-matching placebo | EXPERIMENTAL | - |
| Placebo | EXPERIMENTAL | - |
| Fasinumab | EXPERIMENTAL | - |
| Fasinumab 6 mg SC Q4W and Placebo IV Q8W | EXPERIMENTAL | Participants randomized to the fasinumab 6 mg SC Q4W arm received fasinumab 12 mg SC on Day 1 (loading dose) and then 6 mg SC (planned maintenance dose) at Weeks 4, 8, and 12 for a total of 4 doses. Matching placebo was received via intravenous (IV) infusion Q8W on Day 1 and at Week 8. |
| Fasinumab 9 mg SC Q4W and Placebo IV Q8W | EXPERIMENTAL | Participants randomized to the fasinumab 9 mg SC Q4W arm received 18 mg SC on day 1 (loading dose) and then 9 mg SC (planned maintenance dose) at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo IV Q8W was received on Day 1 and at Week 8. |
| Fasinumab 9 mg IV Q8W and Placebo SC Q4W | EXPERIMENTAL | Participants randomized to the fasinumab 9 mg IV Q8W arm received IV infusions of fasinumab 9 mg on Day 1 and Week 8, for a total of 2 doses. Matching placebo SC Q4W was received on day 1 and at weeks 4, 8, and 12. |
| Placebo SC Q4W and Placebo IV Q8W | EXPERIMENTAL | Participants randomized to the matching placebo subcutaneously (SC) every four weeks (Q4W) arm received SC placebo in a manner similar to the SC loading dose of the active groups (placebo loading dose) on Day 1 and then an SC injection of placebo at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo intravenously (IV) every 8 weeks (Q8W) was received on Day 1 and at Week 8. |
| Group A | EXPERIMENTAL | Group A will receive REGN475 dosing regimen 1 |
| Group B | EXPERIMENTAL | Group B will receive REGN475 dosing regimen 2 |
| Group C | EXPERIMENTAL | Group C will receive REGN475 dosing regimen 3 |
| Group D | EXPERIMENTAL | Group D will receive REGN475 dosing regimen 4 |
| Group E | EXPERIMENTAL | Group E will receive matching placebo |
| placebo injection | PLACEBO_COMPARATOR | - |
| active | EXPERIMENTAL | subcutaneous injection of REGN475 |
| active 2 | EXPERIMENTAL | subcutaneous injection of REGN475 |
| Auto-injector (AI) | EXPERIMENTAL | - |
| Prefilled syringe (PFS) | EXPERIMENTAL | - |
| Dose 1 | EXPERIMENTAL | - |
| Dose 2 | EXPERIMENTAL | - |
| Dose 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Fasinumab | DRUG | Solution for injection in pre-filled syringe |
| Diclofenac | OTHER | NSAID active comparator (capsule) |
| Celecoxib | OTHER | NSAID active comparator (capsule) |
| Matching placebo | DRUG | Fasinumab-matching placebo (solution for injection in pre-filled syringe); NSAID-matching placebo (capsule) |
| Naproxen | DRUG | Pharmaceutical form: Capsule |
| Fasinumab-matching placebo | DRUG | Solution for injection in pre-filled syringe |
| Naproxen-matching placebo | DRUG | Capsule |
| Placebo | DRUG | Participants will receive sub-cutaneous (SC) injections of matching placebo |
| REGN475 | DRUG | - |
| Placebo Injection | DRUG | Placebo Subcutaneous injection |
| Fasinumab AI | DRUG | Self-administered with auto injector |
| Fasinumab PFS | DRUG | Prefilled syringe administered by study staff |
Key Inclusion Criteria (additional criteria may apply at screening): 1. A clinical diagnosis of osteoarthritis (OA) of the knee or hip based on the American College of Rheumatology criteria with radiologic evidence of OA (K-L score ≥2 for the index joint) at the screening visit. 2. Willing to disco...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
REGN475 is an investigational monoclonal antibody being studied for pain conditions, specifically osteoarthritis of the knee and sciatica. It was developed to treat pain associated with knee osteoarthritis and sciatic pain. The clinical program explored its use in patients with these musculoskeletal pain indications.
REGN475 targets nerve growth factor, or NGF, a protein involved in pain signaling. By binding NGF, the antibody is designed to interfere with NGF-mediated pain pathways. NGF is a well-characterized target in musculoskeletal pain research, and REGN475 is a monoclonal antibody directed against this protein.
REGN475 is being developed by Regeneron Pharmaceuticals, Inc., which trades on Nasdaq under the ticker REGN. The drug is also identified as REGN475 (SAR164877), reflecting a collaboration naming convention. Regeneron is the sponsor of the clinical studies conducted for this asset.
REGN475 is in Phase 1 development and is investigational. It has not been approved by the FDA. Clinical work completed to date includes Phase 1 and Phase 2 studies, and no active trials are currently listed for the program.
REGN475 has been studied in completed trials including NCT02447276, a Phase 2 study in knee or hip osteoarthritis pain with 421 patients, NCT00991172, a Phase 2 study in sciatic pain with 159 patients, and NCT00944892, a Phase 1 study in knee osteoarthritis with 200 patients. All were conducted in the United States.
Yes, REGN475 is also known as SAR164877. The dual name REGN475 (SAR164877) appears in trial titles and reflects the same monoclonal antibody asset. Readers searching for either name are looking at the same investigational compound developed by Regeneron Pharmaceuticals.